Ranbaxy Q4 net loss declines sharply to Rs 158.48 crore

Pharma major Ranbaxy Laboratories today reported a drastic drop in net loss at Rs

RELATED ARTICLES

158.48 crore during the fourth quarter ended December 31, 2013.

The company had posted a net loss of Rs 492.44 crore in the corresponding quarter of the last financial year (2012-13), Ranbaxy said in a regulatory filing to the stock exchanges.

It had recorded a net loss of Rs 454.16 crore in Q3 of this fiscal.

Total income from operations of the company rose to Rs 2,893.99 crore from Rs 2,711.21 crore during the same period last year.

Earlier this month, Ranbaxy Laboratories signed an agreement with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis.

The product will be introduced in India and other emerging markets soon, the company had said.

Shares of the company were trading at Rs 328.70, up 2.16 per cent on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Mutual fund stakeholders should focus on better returns in a bullish market

    The association of mutual fund of India (AMFI) has recently capped the commission paid to distributors of mutual fund schemes to a maximum of 1 per ce

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Today's Columns

Roopen Roy

What we can learn from Singapore

Lee Kuan Yew passed away at the age of 91 ...

Rajgopal Nidamboor

Don’t depend too much on ‘heroes’

We all have our own set of ‘heroes’ — not ...

Shona Adhikari

Anjolie Ela Menon, the storyteller, is back

Anjolie Ela Menon, one of India’s most celebrated artists, is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture